Aptar Pharma Acquires PULMOTREE
October 30, 2026
Aptar Pharma acquired Munich-based PULMOTREE, adding its Kolibri non-propellant liquid inhaler technology to Aptar’s pulmonary drug-delivery portfolio. Aptar plans to integrate the platform with its formulation, device-engineering, regulatory, manufacturing, patient-onboarding, and digital-health capabilities to support pharmaceutical partners developing complex inhaled therapies.
- Buyers
- Aptar Pharma
- Targets
- PULMOTREE
- Industry
- Medical Devices
- Location
- Bavaria, Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Ampersand Capital Partners Acquires Purna Pharmaceuticals
February 12, 2026
Healthcare Services
Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider for liquid and semi-solid pharmaceutical dosage forms. The investment is intended to enable collaboration with Ampersand portfolio company MedPharm to build a trans-Atlantic topical and transdermal drug formulation and manufacturing partnership for global pharmaceutical clients.
-
Aptar Pharma Acquires Mod3 Pharma's Clinical Trial Materials Manufacturing Capabilities
July 15, 2025
Pharmaceuticals
Aptar Pharma has acquired the Phase 1 and 2 clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The deal adds cGMP fill-and-finish, high-potency API suites and biologics capabilities at a Boonton, New Jersey facility to Aptar's drug delivery and early-stage development services to accelerate adoption of its delivery technologies.
-
Astellas Pharma to Acquire Propella Therapeutics
November 15, 2023
Biotechnology
Astellas Pharma, through a US subsidiary, has entered into a merger agreement to acquire Propella Therapeutics for approximately $175 million in cash. Propella is developing PRL-02 (abiraterone decanoate), a next-generation long-acting prodrug targeting prostate cancer, which is currently in Phase 1 with plans to enter Phase 2a in 2024.
-
Aileron Therapeutics Acquires Lung Therapeutics
October 31, 2023
Biotechnology
Aileron Therapeutics, Inc. (NASDAQ: ALRN) completed a stock-for-stock acquisition of Lung Therapeutics, Inc., bringing the clinical-stage pulmonary and fibrosis-focused pipeline (including lead candidate LTI-03) into Aileron's portfolio. Immediately after the acquisition Aileron arranged a private placement led by Bios Partners (with participation from Nantahala Capital and others) to raise approximately $18 million to fund ongoing development, including a Phase 1b trial of LTI-03.
-
Electromedical Products International Acquires Pulvinar Neuro
March 17, 2022
Medical Devices
Electromedical Products International (EPI) has acquired Pulvinar Neuro, a research-oriented medical device company focused on closed-loop neuromodulation and digital therapeutics. The deal expands EPI's scientific and research capabilities to accelerate development and commercialization of Pulvinar's transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics.
-
AptarGroup Completes Acquisition of Majority Stake in Voluntis (Theraxium Digital Therapeutics)
September 2, 2021
Healthcare Services
AptarGroup, Inc. entered into exclusive negotiations and subsequently completed the acquisition of a majority stake (approximately 64.6%) in Voluntis, a digital therapeutics company. The transaction was followed by a mandatory cash tender offer to acquire Voluntis’ remaining shares at €8.70 per share, with a potential squeeze-out if regulatory conditions are met.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.